Influence of changes in blood pressure on cerebral perfusion and oxygenation.
Cerebral autoregulation (CA) is a critical process for the maintenance of cerebral blood flow and oxygenation. Assessment of CA is frequently used for experimental research and in the diagnosis, monitoring, or prognosis of cerebrovascular disease; however, despite the extensive use and reference to static CA, a valid quantification of "normal" CA has not been clearly identified. While controlling for the influence of arterial Pco(2), we provide the first clear examination of static CA in healthy humans over a wide range of blood pressure. In 11 healthy humans, beat-to-beat blood pressure (radial arterial), middle cerebral artery blood velocity (MCAv; transcranial Doppler ultrasound), end-tidal Pco(2), and cerebral oxygenation (near infrared spectroscopy) were recorded continuously during pharmacological-induced changes in mean blood pressure. In a randomized order, steady-state decreases and increases in mean blood pressure (8 to 14 levels; range: approximately 40 to approximately 125 mm Hg) were achieved using intravenous infusions of sodium nitroprusside or phenylephrine, respectively. MCAv(mean) was altered by 0.82+/-0.35% per millimeter of mercury change in mean blood pressure (R(2)=0.82). Changes in cortical oxygenation index were inversely related to changes in mean blood pressure (slope=-0.18%/mm Hg; R(2)=0.60) and MCAv(mean) (slope=-0.26%/cm . s(-1); R(2)=0.54). There was a progressive increase in MCAv pulsatility with hypotension. These findings indicate that cerebral blood flow closely follows pharmacological-induced changes in blood pressure in otherwise healthy humans. Thus, a finite slope of the plateau region does not necessarily imply a defective CA. Moreover, with progressive hypotension and hypertension there are differential changes in cerebral oxygenation and MCAv(mean).
Lucas
Samuel J E
SJ
Department of Physiology, University of Otago, Dunedin, New Zealand.
Tzeng
Yu Chieh
YC
Galvin
Sean D
SD
Thomas
Kate N
KN
Ogoh
Shigehiko
S
Ainslie
Philip N
PN
D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology*; D007022:Hypotension / Q000139:chemically induced* / Q000503:physiopathology*; D016014:Linear Models; D008297:Male; D009599:Nitroprusside / Q000008:administration & dosage* / Q000009:adverse effects; D010100:Oxygen / Q000097:blood; D010656:Phenylephrine / Q000008:administration & dosage* / Q000009:adverse effects; D011673:Pulsatile Flow / Q000187:drug effects / Q000502:physiology; D012016:Reference Values; D019265:Spectroscopy, Near-Infrared; D013990:Tidal Volume; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D009599:Nitroprusside; D010656:Phenylephrine; D010100:Oxygen